Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 2465 • ACR Convergence 2025
CD19/BCMA Dual-Targeting FasTCAR-T Cells GC012F (AZD0120) in patients with refractory Systemic Lupus Erythematosusm: an open-label, single-center Phase I study
chunmei Wu¹, Yakai Fu², Jia Liu³, Yan Ye⁴, Ran Wang⁵, Xintong Feng³, Lianjun Shen⁶, Peiying Li⁵, Shuang Ye⁵ and Qiong Fu⁷, ¹Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, Shanghai, China (People's Republic), ²Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Shanghai, China (People's Republic), ³Astrazeneca, Shanghai, China (People's Republic), ⁴Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (People's Republic), ⁵Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, Shanghai, Shanghai, China (People's Republic), ⁶Astrazeneca, Shanghai, Shanghai, China (People's Republic), ⁷Renji Hospital, Shanghai, Shanghai, China
Background/Purpose: GC012F (AZD0120) is a CD19/B cell maturation antigen (BCMA) dual-targeting chimeric antigen receptor T-cell (CAR-T) developed on the novel FasTCAR-T platform with next-day manufacturing,…
Abstract Number: 2447 • ACR Convergence 2025
Longitudinal Disease Activity Trajectories in Patients with Systemic Lupus Erythematosus Treated with Belimumab
Fumin Qi¹, Yin Zhao², Wei Bian¹, Jian Hao¹, Na zhang¹ and Wei Wei¹, ¹Tianjin Medical University General Hospital, Tianjin, China (People's Republic), ²Affiliated Hospital of Yunnan University, Yunnan, China (People's Republic)
Background/Purpose: To investigate the longitudinal disease activity trajectories in patients with systemic lupus erythematosus (SLE) treated with belimumab.Methods: A prospective cohort of SLE treated with…
Abstract Number: 2430 • ACR Convergence 2025
Disease Activity Independently Correlates with Cognitive Impairment in Systemic Lupus Erythematosus
Steven Beiser¹, Asma Qureshi¹, Komel Safdar², Zachary Orban¹, Mary Carns², Vanessa Manada De Lobos¹, Cecilia Stumpf³, Mohammad Daud Khan¹, Tyler Therron⁴, Anh Chung¹, Katherine Puev¹, Neil Pillai¹, Kathleen Aren⁵, John F Seagrist², Jing Song⁶, Jason Ross¹, Harris R Perlman², Yvonne Lee², Deborah Rachelle Winter⁷, Borna Bonakdarpour¹, Mariam Siddiqui⁸, Laura Arneson², Rosalind Ramsey-Goldman⁹, Lutfiyya muhammad⁹, Mary Mahieu⁹, Irene Blanco¹⁰, Eric Larson¹, Elena Grebenciucova¹ and Carla Marie Cuda², ¹Northwestern University, Chicago, ²Northwestern University, Chicago, IL, ³Northwestern University, Elmhurst, IL, ⁴Northwestern Feinberg School of Medicine, Chicago, IL, ⁵Northwestern University Division of Rheumatology, Chicago, IL, ⁶Northwestern University Feinberg School of Medicine, Worthington, MN, ⁷Northwestern University, Skokie, IL, ⁸Northwestern, Chicago, IL, ⁹Northwestern University Feinberg School of Medicine, Chicago, IL, ¹⁰Northwestern University, Oak Park, IL
Background/Purpose: Mechanisms driving cognitive impairment (CI) in systemic lupus erythematosus (SLE) remain poorly understood; conflicting results exist regarding the relationship between CI and disease activity.…
Abstract Number: 2412 • ACR Convergence 2025
Evolving Trends in Pulmonary Arterial Hypertension among Systemic Lupus Erythematosus Patients: A Nationwide Analysis
Maria Romero Noboa¹, Faria Sami², Almurtada Razok³ and Shahzad Ahmed Sami⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²The University of Alabama at Birmingham, Birmingham, AL, ³John H Stroger Jr Hospital of Cook County, Chicago, IL, ⁴DCH Regional Medical Center, Birmingham
Background/Purpose: Pulmonary arterial hypertension (PAH) is a rare manifestation of Systemic Lupus Erythematosus (SLE) with increased morbidity and mortality. It has historically been underdiagnosed in…
Abstract Number: 2393 • ACR Convergence 2025
Improving Clinical Outcomes In SLE Arthritis Trials: Post-Hoc Analysis Of A Prospective Intervention Study
Samuel Wood¹, Khaled Mahmoud², Md Yuzaiful Md Yusof², Philip Conaghan², Elizabeth Hensor² and Ed Vital³, ¹University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ²University of Leeds, Leeds, United Kingdom, ³University of Leeds, Leeds, England, United Kingdom
Background/Purpose: Musculoskeletal (MSK) manifestations of SLE are the most frequently assessed domain in clinical trials. Optimal MSK assessment is contested; candidates include the binary or…
Abstract Number: 2293 • ACR Convergence 2025
CLN-978, a CD19 x CD3-Directed T Cell Engager, Leads to Rapid and Deep B Cell Depletion In Vitro and In Vivo, Supporting Clinical Development Across Multiple Autoimmune Diseases
Ella Ioffe, Karsten Sauer, Todd Shearer, Jennifer Michaelson, Jeffrey Jones, Yue Zhang, Stephen Wax and Antoine Sreih, Cullinan Therapeutics Inc, Cambridge, MA
Background/Purpose: Treatments depleting CD19-expressing B cells have shown benefit in a range of autoimmune diseases. T cell engagers (TCE) offer off-the-shelf convenience, the predictable pharmacokinetic/pharmacodynamic…
Abstract Number: 2198 • ACR Convergence 2025
Sociocultural Influences on Pregnancy Planning for Individuals Diagnosed with SLE in an Urban Hispanic Population: A Qualitative Study with Considerations for a Holistic Approach
Andrew Ramirez¹, Alexa Montes de Oca¹, Martha Delgado¹, Mellissa withers¹ and Leanna Wise², ¹University of Southern California, Los Angeles, ²LAGMC/Keck Medicine of USC, Los Angeles
Background/Purpose: As systemic lupus erythematosus (SLE) often affects women of child-bearing age, understanding how this population makes reproductive health decisions is critical for well-rounded healthcare.…
Abstract Number: 1915 • ACR Convergence 2025
Innovative Clinical Trial Recruitment Approaches in Lupus Research: LuCIN Site Perspectives on Use of Social Media and Artificial Intelligence
Brandon Jackson¹, Roberto Caricchio², Saira Sheikh³, Meenakshi Jolly⁴, Jennifer Meriwether⁵, Taylor Irons⁶, Taylor Adjei⁷, Caroline Donovan⁸, Carla Menezes⁷, Courtney Canton⁹, Aimee Williams¹⁰, Maya Merrell⁹ and Stacie Bell¹¹, ¹Lupus Therapeutics, Miami, FL, ²University of Massachusetts Chan Medical School, Worcester, MA, ³University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁴Rush University, Chicago, IL, ⁵Lupus Therapeutics, Westminster, CO, ⁶Lupus Therapeutics, Houston, TX, ⁷Lupus Therapeutics, New York, NY, ⁸Lupus Therapeutics, Charlottesville, VA, ⁹Lupus Therapeutics, Charleston, SC, ¹⁰Lupus Therapeutics, Raleigh, NC, ¹¹Lupus Therapeutics, Lakewood, CO
Background/Purpose: Lupus disproportionately impacts racial and ethnic minorities, yet these groups remain underrepresented in clinical trials. Lupus Therapeutics, overseeing the Lupus Clinical Investigators Network (LuCIN),…
Abstract Number: 1845 • ACR Convergence 2025
Immune Cell Profiles and Transcriptomic Signatures of Atherosclerosis in Systemic Lupus Erythemathosus
Rodolfo Martinez-Canales¹, Andres M. Ortiz-Rios², Braulio R. Avalos-Garcia², Eva Abigaid Galindo-Calvillo², Mario Cesar Salinas-Carmona¹, Noe Macias-Segura¹, Lorena Perez-Barbosa², Dionicio A. Galarza-Delgado³ and Cassandra Michele Skinner-Taylor², ¹Immunology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, ²Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, ³Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico
Background/Purpose: Systemic lupus erythematosus (SLE) significantly increases the risk of premature atherosclerosis, contributing to long-term morbidity and mortality. Traditional cardiovascular risk factors do not fully…
Abstract Number: 1777 • ACR Convergence 2025
Granzyme B as a regulator of interferon alpha production in cutaneous lupus erythematosus
Touraj Khosravi¹, Ahmed Eldaboush², Darae Kang³ and Victoria Werth², ¹Department of Dermatology, Perelman Shool of Medicine, University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania, Potomac, MD
Background/Purpose: Recent studies have shown that monocytes, macrophages, and conventional DCs, but not plasmacytoid dendritic cells (pDC), are major sources of IFNα in cutaneous lupus…
Abstract Number: 1707 • ACR Convergence 2025
Racial and Ethnic Disparities in Kidney Transplant Outcomes Among Patients With Systemic Lupus Erythematosus (SLE): A 20-Year Analysis Spanning Before and After the 2014 Kidney Allocation System Revision
Soziema Salia¹, Boniface Mensah², Ufuoma Mamoh¹, Gilava Hedayati¹, Terrylyna Baffoe-Bonnie³, Joan Morny⁴ and Christhopher Haas³, ¹MedStar Health Georgetown University (Baltimore) Internal Medicine Program, Baltimore, MD, ²MedStar Health Georgetown University (Baltimore) Internal Medicine Program, Baltimore, CA, ³MedStar Health Georgetown University (Baltimore) Internal Medicine Program, Baltimore, ⁴Piedmont Athens Regional Internal Medicine Residency Program, Athens, GA
Background/Purpose: Systemic lupus erythematosus (SLE) is a leading cause of end-stage kidney disease (ESKD) in young women, particularly among racial and ethnic minorities. Kidney transplantation…
Abstract Number: 1506 • ACR Convergence 2025
Perspectives on Clinical Trial Participation for Novel Advanced Therapies: A Focus Group Study in Systemic Lupus Erythematosus (SLE)
Olivia A. Stein¹, Jennifer Lee¹, Evelyne Vinet², Arielle Mendel³, Christian Pineau⁴, Leanne Mielczarek⁵ and Sasha Bernatsky², ¹Research Institute of the McGill University Health Centre, Montreal, Canada, ²Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³McGill University Health Centre, Montreal, Canada, ⁴McGill University, Montréal, QC, Canada, ⁵Lupus Canada, Newmarket, Canada
Background/Purpose: Our objective is to identify barriers and facilitators perceived by people with systemic lupus erythematosus (SLE) regarding participation in clinical trials for novel/advanced agents,…
Abstract Number: 1536 • ACR Convergence 2025
Evaluating Systemic Lupus Erythematosus Remission Among Patients Initiating Belimumab in a Real-World Setting in the USA
Aarat M Patel¹, Renee L. Gennarelli², Temitope Bello², Ali Bonakdar² and Karen Worley³, ¹GSK, US Medical Affairs, Durham, NC, ²Cencora, Real-World Evidence, Conshohocken, PA, ³GSK, Global Real-World Evidence & Health Outcomes Research, Collegeville, PA
Background/Purpose: The Definition Of Remission In SLE (DORIS) criteria were developed to provide alignment on defining remission in patients with SLE.1,2 Belimumab (BEL) treatment increases…
Abstract Number: 1517 • ACR Convergence 2025
The Chinese Experience with Telitacicept in Lupus Nephritis Management: 51-Patient Cohort Analysis on Therapeutic Outcomes and Safety Parameters
Aijing Liu¹, Fei Chang² and Qiuhong Xu¹, ¹Department of Rheumatology and Immunology, The Second Hospital of Hebei Medical University, Shijiazhuang, China (People's Republic), ²Department of Rheumatology and Immunology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China (People's Republic)
Background/Purpose: Lupus nephritis (LN), affects 30%-50% of systemic lupus erythematosus (SLE) patients, a major contributor to SLE-related mortality. Telitacicept, an innovative recombinant fusion protein, disrupts…
Abstract Number: 1494 • ACR Convergence 2025
Comparing Childhood-Onset Versus Adult-Onset Systemic Lupus Erythematosus Young Adults’ Lived Employment Experiences
NILOFAR JAHAGHI¹, Michael Golding², Fareha Nishat³, Kaitlyn Merrill², Diane Lacaille⁴, Umut Oguzoglu², Roberta Woodgate², Jennifer Stinson⁵, Christine Peschken⁶, Zahi Touma⁷, Jennifer Protudjer² and Lily Lim⁶, ¹Karolinska Institutet, Stockholm, Sweden, ²University of Manitoba, Winnipeg, Canada, ³University of Toronto, Toronto, Canada, ⁴Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ⁵The Hospital for Sick Children, Toronto, ON, Canada, ⁶University of Manitoba, Winnipeg, MB, Canada, ⁷University of Toronto, Toronto, ON, Canada
Background/Purpose: Young adulthood (18-30 years) is a life stage with many transitions. Young adults with Systemic Lupus Erythematosus must navigate this period while living with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].